Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Pabinafusp Alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Pabinafusp Alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Diclofenac etalhyaluronate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Diclofenac etalhyaluronate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Serdexmethylphenidate/Dexmethylphenidate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Serdexmethylphenidate/Dexmethylphenidate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Utidelone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Utidelone: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Viloxazine Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Viloxazine Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Eflapegrastim Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Eflapegrastim: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Leuprolide Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Leuprolide Mesylate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
![[18F]DCFPyL Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static.patsnap.com/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
8 min read
[18F]DCFPyL Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
[18F]DCFPyL: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Elasomeran/Imelasomeran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Elasomeran/Imelasomeran: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
APSCTC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
APSCTC: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Nexiguran ziclumeran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Nexiguran ziclumeran: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Zelestrocel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Zelestrocel: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.